Influence of the dengue serotype, previous dengue infection, and plasma viral load on clinical presentation and outcome during a dengue-2 and dengue-4 co-epidemic.

Martinique experienced a dengue outbreak with co-circulation of DENV-2 and DENV-4. In an emergency department-based study, we analyzed whether the clinical presentation and outcome of adult patients were related to serotype, immune status, or plasma viral load. Of the 146 adult patients who had confirmed dengue infection, 91 (62.3%) were classified as having classic dengue fever, 11 (7.5%) fulfilled World Health Organization criteria for dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS), 21 other patients (14.4%) presented with at least one typical feature of DHF/DSS [i.e., internal hemorrhage, plasma leakage, marked thrombocytopenia (platelet count < or = 50,000 platelets/mm(3)) and/or shock], and 23 further patients (15.8%) had unusual manifestations. Four patients died. Severe illness was more frequent in patients with secondary dengue infection (odds ratio, 7.18; 95% confidence interval, 3.1-16.7; P < 0.001). Multivariate regression analysis showed that gastrointestinal symptoms and other unusual manifestations were independently associated with DENV-2 infection, whereas cough and DHF/DSS features were independently associated with secondary immune response. A high plasma viral load was associated with DENV-2 infection, increased serum liver enzymes, and with DHF/DSS features in patients presenting after the third day of illness. The most severe cases of dengue resulted from the combined effects of DENV-2 and secondary infection.

[1]  S. Green,et al.  Immunopathological mechanisms in dengue and dengue hemorrhagic fever , 2006, Current opinion in infectious diseases.

[2]  A. Nisalak,et al.  Early clinical and laboratory indicators of acute dengue illness. , 1997, The Journal of infectious diseases.

[3]  E. Chungue,et al.  Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996–1997 dengue‐2 outbreak in French Polynesia , 2000, Journal of medical virology.

[4]  S. Halstead,et al.  Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. , 2001, The American journal of tropical medicine and hygiene.

[5]  O. Pybus,et al.  Invasion and Maintenance of Dengue Virus Type 2 and Type 4 in the Americas , 2005, Journal of Virology.

[6]  G. Screaton,et al.  T cell responses and dengue haemorrhagic fever. , 2006, Novartis Foundation symposium.

[7]  Joshua S. Davis,et al.  Rhabdomyolysis associated with dengue virus infection. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  M. Guzmán,et al.  Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges. , 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[9]  Charles H. Hoke,et al.  SEROTYPE-SPECIFIC DENGUE VIRUS CIRCULATION AND DENGUE DISEASE IN BANGKOK, THAILAND FROM 1973 TO 1999 , 2003 .

[10]  C. King,et al.  Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Duane J. Gubler,et al.  Dengue and Dengue Hemorrhagic Fever , 1998, Clinical Microbiology Reviews.

[12]  R. López-Vélez,et al.  Severe dengue virus infection in travelers: risk factors and laboratory indicators. , 2007, The Journal of infectious diseases.

[13]  Kuender D Yang,et al.  Implications of previous subclinical dengue infection but not virus load in dengue hemorrhagic fever. , 2006, FEMS immunology and medical microbiology.

[14]  E. Chungue,et al.  Dengue: an evaluation of dengue severity in French Polynesia based on an analysis of 403 laboratory‐confirmed cases , 1999, Tropical medicine & international health : TM & IH.

[15]  Jacqueline L Deen,et al.  The WHO dengue classification and case definitions: time for a reassessment , 2006, The Lancet.

[16]  J. Rigau-Pérez,et al.  Severe dengue: the need for new case definitions. , 2006, The Lancet. Infectious diseases.

[17]  Tom Solomon,et al.  Clinical diagnosis and assessment of severity of confirmed dengue infections in Vietnamese children: is the world health organization classification system helpful? , 2004, The American journal of tropical medicine and hygiene.

[18]  A. Nisalak,et al.  Mechanisms of hemorrhage in dengue without circulatory collapse. , 2001, The American journal of tropical medicine and hygiene.

[19]  M. Guzmán,et al.  Dengue: an update. , 2002, The Lancet. Infectious diseases.

[20]  M. Guzmán,et al.  Race: a risk factor for dengue hemorrhagic fever , 2006, Archives of Virology.

[21]  Tao Dong,et al.  Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever , 2003, Nature Medicine.

[22]  L. Rosen,et al.  Clinical and laboratory observations on patients with primary and secondary dengue type 1 infections with hemorrhagic manifestations in Fiji. , 1977, The American journal of tropical medicine and hygiene.

[23]  A. Nisalak,et al.  Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. , 2000, The Journal of infectious diseases.

[24]  A. Nisalak,et al.  Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. , 2002, The Journal of infectious diseases.

[25]  Angel Balmaseda,et al.  Short report: assessment of the World Health Organization scheme for classification of dengue severity in Nicaragua. , 2005, The American journal of tropical medicine and hygiene.

[26]  D. Burke,et al.  Antibody-dependent enhancement in dengue virus infections. , 2006, The Journal of infectious diseases.

[27]  A. Wilder-Smith,et al.  Fulminant hepatitis in dengue haemorrhagic fever. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[28]  N. M. Dung,et al.  Rapid serologic diagnosis of dengue virus infection using a commercial capture ELISA that distinguishes primary and secondary infections. , 1999, The American journal of tropical medicine and hygiene.

[29]  G. Crane Dengue haemorrhagic fever: diagnosis, treatment, prevention and control , 1999 .

[30]  M. Guzmán,et al.  Evaluation of immunoglobulin M and G capture enzyme-linked immunosorbent assay Panbio kits for diagnostic dengue infections. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[31]  R. Césaire,et al.  Reemergence of Dengue Virus Type 4, French Antilles and French Guiana, 2004–2005 , 2006, Emerging infectious diseases.

[32]  R. Lanciotti,et al.  Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction , 1992, Journal of clinical microbiology.

[33]  S. Halstead Dengue in the Americas and Southeast Asia: do they differ? , 2006, Revista panamericana de salud publica = Pan American journal of public health.

[34]  X. de Lamballerie,et al.  Complete genomic sequence of a dengue type 2 virus from the French West Indies. , 2000, Biochemical and biophysical research communications.

[35]  E. Harris,et al.  Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. , 2005, The American journal of tropical medicine and hygiene.

[36]  A. Rothman Immunology and immunopathogenesis of dengue disease. , 2003, Advances in virus research.

[37]  S. Halstead,et al.  Pathogenesis of dengue: challenges to molecular biology. , 1988, Science.

[38]  S. Halstead,et al.  Epidemiologic studies on Dengue in Santiago de Cuba, 1997. , 2000, American journal of epidemiology.

[39]  M. Guzmán,et al.  Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. , 1990, The American journal of tropical medicine and hygiene.